Clinical features of primary sclerosing cholangitis and inflammatory bowel disease / 中华内科杂志

Objective: To explore disease characteristics of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) and compare the differences between PSC with and without IBD. Methods: Study design was cross sectional. Forty-two patients with PSC who were admitted from January 2000 to January 2021 were included. We analyzed their demographic characteristics, clinical manifestations, concomitant diseases, auxiliary examination, and treatment. Results: The 42 patients were 11-74(43±18) years of age at diagnosis. The concordance rate of PSC with IBD was 33.3%, and the age at PSC with IBD diagnosis was 12-63(42±17) years. PSC patients with IBD had higher incidences of diarrhea and lower incidences of jaundice and fatigue than in those without IBD (all P<0.05). Alanine aminotransferase, total bilirubin, direct bilirubin, total bile acid and carbohydrate antigen 19-9 levels were higher in PSC patients without IBD than in those with IBD (all P<0.05). The positive rates for antinuclear antibodies and fecal occult blood were higher in PSC patients with IBD than in those without IBD (all P<0.05). Patients with PSC complicated with ulcerative colitis mainly experienced extensive colonic involvement. The proportion of 5-aminosalicylic acid and glucocorticoid application in PSC patients with IBD was significantly increased compared with that of PSC patients without IBD (P=0.025). Conclusions: The concordance rate of PSC with IBD is lower at Peking Union Medical College Hospital than in Western countries. Colonoscopy screening may benefit PSC patients with diarrhea or fecal occult blood-positive for early detection and diagnosis of IBD.

Can fecal calprotectin reflect your colonic status?

Background: Organic colonic manifestation may be difficult to be differentiated from functional one. Inflammatory bowel disease (IBD) is a common chronic inflammatory and destructive disease of the bowel wall. Chronic inflammation is associated with ulcerations, strictures, perforations, and it is a risk factor for dysplasia and cancer. To reduce these long-standing complications, IBD patients are in a continuous need for early diagnosis1. Markers, such as erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP), fecal calprotectin (FC) have been widely used as noninvasive parameters for IBD monitoring. We aimed, in this current study, to evaluate the value of fecal calprotectin and other noninvasive biomarkers in predicting abnormal histologic findings in patients undergoing colonoscopy.in addition to determine the cutoff value which predict IBD2. Methods: The present prospective study included 160 patients with complaint of colicky abdominal pain with frequent diarrhea associated with mucous and infrequent bleeding per rectum for more than 6 months. They presented partial improvement with medication and recurrence once stopping the treatment These patients had been recently diagnosed with IBD at many primary healthcare centers covering the areas of the Kafrelsheikh and Zagazik governorate in the North of Egyptian Nile delta. After complete history, clinical examination, and laboratory investigation, they were referred to the IBD clinic at Kafrelsheikh University Hospital for assessment and ileocolonoscopy with biopsies. Results: There was a wide spectrum of age of the studied patients, with mean age 40.12±7.88 (minimum 18 and maximum 56 years). Regarding gender, males represented 87.5% of the studied patients. Forty percent of the patients with colonic manifestation were smokers, 57% preferred a spicy diet, and the majority had low educational level (77.5%). Forty percent had obvious blood in stool, 55% had occult blood, and raised ESR CRP occurred in 32.5% and 50%, respectively. Fecal calprotectin cutoff was>159, with sensitivity 92.8% and specificity 97.5%. Conclusions: Biomarkers (FC, ESR, CRP) can be used as noninvasive parameters for the early diagnosis and prediction of organic colonic disease. Fecal calprotectin in the IBD group revealed significant area under the curve (AUC) values and cutoff> 159, with sensitivity 92.8% and specificity 97.5%. (AU)

Proctitis y enfermedad perianal de causa infecciosa: una mirada más allá de la enfermedad inflamatoria intestinal / Infectious proctitis and perianal disease: a gaze beyond inflammatory bowel disease

Resumen La proctitis infecciosa secundaria a una enfermedad de transmisión sexual ha aumentado en incidencia y deben ser consideradas especial-mente en varones homosexuales o bisexuales con síntomas rectales. Presentamos un paciente con una proctitis y enfermedad perianal por Chlamydia trachomatis que podría haber sido diagnosticado con otra enfermedad ano-rectal como es la enfermedad inflamatoria intestinal, si la historia clínica no hubiese sido considerada. Un alto nivel de sospecha es necesario para evitar un diagnóstico incorrecto, retrasar el tratamiento antimicrobiano y el desarrollo de complicaciones.

Abstract Infectious proctitis by sexually transmitted diseases are increasing in incidence and should be considered in homosexual patients with rectal symptoms. In this case, we show a patient with proctitis and perianal disease caused by Chlamydia trachomatis that could be diagnosed as another anorectal disease such as inflammatory bowel disease if the clinical history is not taken into account. A high level of suspicion is crucial, in order to avoid an incorrect diagnosis, delayed antibiotic therapy and the development of complications.

Non-specific colitis among patients with colitis: frequency and relation to inflammatory bowel disease, a prospective study / Colite inespecífica entre pacientes com colite: estudo prospectivo sobre sua frequência e relação com doença inflamatória intestinal

Abstract Background and study aim: The term non-specific colitis refers to an inflammatory condition of the colon that microscopically lacks the characteristic features of any specific form of colitis and is commonly seen in pathology reports of colonoscopy biopsies. In fact, it has been questioned whether it is a separate pathological entity or it is merely an intermediate stage in the course of inflammatory bowel disease. This study was conducted to estimate the prevalence of non-specific colitis among patients with colitis and characterize its natural history over a 6 months year period. Patients and methods: Eighty adult patients presented for colonoscopy were enrolled. In the final analysis they were divided into Group A; the non-specific colitis Group and Group B; the inflammatory bowel disease Group. All patients were subjected to: full history taking, full clinical examination, laboratory investigations: which included stool analysis, CRP, ESR, complete colonoscopy and entire random colon biopsies for histopathological examination. Results: Group A included 67 patients (83.75%) while Group B included 13 (16.25%) patients. Patients with IBD had clinical and laboratory features of inflammation significantly higher than patients with non-specific colitis. Six patients (8.95%) of non-specific colitis group developed histologic features of florid inflammatory bowel disease after 6 months. There were no independent predictors of this conversion. Conclusion: Among our 80 patients with colonoscopy and biopsy 67 (83.75%) were diagnosed as non-specific colitis and out of them 6 patients (8.95%) were reexamined after 6 months and proved to have inflammtory bowel disese this change was not linked to predictive factors.

Resumo Introdução e objetivos: O termo colite inespecífica (CI) refere-se a uma condição inflamatória do cólon que microscopicamente não apresenta características de qualquer forma específica de colite; é comumente observada em relatórios patológicos de biópsias de colonoscopia. De fato, tem-se questionado se esta seria uma entidade patológica separada ou apenas um estágio intermediário no curso da DII. Este estudo foi realizado para estimar a prevalência de CI entre pacientes com colite e caracterizar seu curso durante um período de seis meses. Pacientes e métodos: O estudo incluiu 80 pacientes adultos que se apresentaram para colonoscopia. Na análise, os pacientes foram divididos em dois grupos: grupo A (CI) e grupo B (DII) Todos os pacientes foram submetidos a anamnese completa, exame clínico completo e investigações laboratoriais que incluíram análise de fezes, PCR, VHS, colonoscopia completa e biópsias aleatórias de cólon para exame histopatológico. Resultados: Do total de pacientes, 67 foram alocados no grupo A (83,75%) e 13 (16,25%) no grupo B. Os pacientes com DII apresentavam sinais clínicos e laboratoriais de inflamação significativamente maiores do que o observado em pacientes com CI. Seis pacientes (8,95%) do grupo CI desenvolveram características histológicas de DII florida após seis meses. Não foram identificados preditores independentes para essa conversão. Conclusão: Entre os 80 pacientes submetidos a colonoscopia e biópsia, o diagnóstico de CI foi feito em 67 (83,75%); destes, seis pacientes (8,95%) foram reexaminados após seis meses e apresentaram DII, sendo que essa conversão não foi associada a fatores preditivos.

Caso Clínico: Enfermedad de Crohn en Pediatría, el Desafío de un Diagnóstico Temprano / Case Report: Crohn´s Disease in Pediatrics, the Challenge of an Early Diagnosis

INTRODUCCIÓN: La enfermedad de Crohn, clasificada como una enfermedad inflamatoria intestinal, es una patología inflamatoria crónica con afectación transmural y segmentaria de cualquier parte del tracto digestivo. Se caracteriza por presentar sintomatología clásica como dolor abdominal, diarrea y pérdida de peso; en la población pediátrica ocasiona alteración de la velocidad del crecimiento y desarrollo sexual. Un diagnóstico oportuno y el establecimiento de un tratamiento eficaz son elementales para obtener remisión y garantizar la calidad de vida del paciente. CASO CLÍNICO: Paciente de sexo femenino, de 12 años de edad; consultó por historia de un mes de evolución, caracterizada por fiebre y sintomatología abdominal inespecífica, la misma que incluyó: dolor abdominal, nausea, vómito, pérdida de peso y poliartralgias. Posteriormente el cuadro se exacerbó, presentando deposiciones líquidas sanguinolentas, motivo por el que se decidió su admisión hospitalaria. EVOLUCIÓN: Se descartó patología infecciosa o inmunológica; se realizó endoscopía y colonoscopía donde se encontraron lesiones erosivas hemorrágicas en ciego. El estudio histopatológico fue compatible con enfermedad de Crohn. CONCLUSIÓN: La enfermedad de Crohn, constituye una patología a considerarse en la lista de diagnósticos diferenciales del paciente que consulta por sintomatología abdominal inespecífica. Si bien su prevalencia e incidencia son bajas en la población local, las consecuencias relacionadas con la afectación del desarrollo pondoestatural, desarrollo sexual y la salud psicosocial del paciente; obligan el establecimiento de un diagnóstico y tratamiento oportunos(au)

BACKGROUND: Crohn's disease, classified as an inflammatory bowel disease, is a chronic inflammatory condition that causes transmural and segmental involvement of any part of the digestive tract. It is characterized by presenting classic symptoms such as abdominal pain, diarrhea and weight loss; in pediatric population affects growth and sexual development. An opportune diagnosis¿ and the establishment of an effective treatment are essential to obtain remission and guarantee the quality of life. CASE REPORT: 12 year-old, female patient; with 1 month history of fever and nonspecific abdominal symptoms that include abdominal pain, nausea, vomiting, weight loss and polyarthralgia. Later, the patient presented bloody stools, being admitted for the respective evaluation. EVOLUTION: Infectious and immunological origin was ruled out; an endoscopy and colonoscopy were performed; erosive hemorrhagic lesions were found in the cecum. The histopathological study was compatible with Crohn's disease. CONCLUSION: Crohn's disease is an entity to be considered in the list of differential diagnosis of the patient who complaints of nonspecific abdominal symptoms. Although its prevalence and incidence are low in local population, the consequences related to the affectation of pondoestatural development, sexual development and the psychosocial health of the patient; force the establishment of an opportune diagnosis and treatment.(au)

Calprotectina fecal: utilidad en el diagnóstico diferencial de enfermedad inflamatoria intestinal y síndrome intestino irritable en adultos / Fecal Calprotectin: utility in the differential diagnosis of inflammatory bowel disease and irritable bowel syndrome in adults

Differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be complex as their symptoms are often similar and unspecific. Fecal biomarkers could be useful to select patients with suspected organic diseases for colonoscopy, with the aim to improve early diagnosis and to avoid unnecessary invasive studies. Fecal calprotectin (FC) is a protein found mainly in neutrophils that is released into the feces as a result of cell disruption and apoptosis. Currently, FC is a simple and non-invasive biomarker of intestinal inflammation. Inflammatory gastrointestinal disorders are associated with high levels of FC, as occurs in IBD. This review focuses on FC as a useful tool for differential diagnosis between IBS and IBD in adults. (AU)

Avaliação clínica, endoscópica e histopatológica de cães com doença inflamatória intestinal / Clinical, endoscopic and histopathological evaluation of dogs with inflammatory bowel disease

O presente estudo teve como objetivo avaliar macro e microscopicamente a mucosa gastrintestinal de cães domiciliados, que apresentaram sinais gastrintestinais crônicos, por meio de exame endoscópico e da avaliação histopatológica. Os sinais clínicos, a macro e a microscopia das mucosas gástrica e duodenal foram correlacionados. Foram avaliados 20 cães de diferentes raças, sendo 7 machos e 13 fêmeas, com idade variando entre 1,7 a 15,8 anos, que apresentavam cronicidade dos sinais característicos da Doença Inflamatória Intestinal (DII). O estudo foi prospectivo e transversal, realizado em cães atendidos no Hospital Universitário de Medicina Veterinária da Universidade Federal Fluminense (HUVET - UFF) e em clínicas privadas do município do Rio de Janeiro. Amostras de mucosa gastroduodenal foram obtidas por meio de biópsia endoscópica e foram processadas por técnica histológica de rotina e coradas por Hematoxilina-Eosina e Giemsa. As amostras foram submetidas à análise histopatológica para pesquisa de bactérias espiraladas sugestivas de Helicobacter spp. O teste rápido da urease também foi realizado. Os sinais clínicos, e os achados macro e microscópicos foram confrontados e correlacionados. Neste estudo, foi possível estabelecer correlação positiva entre a perda de peso e a presença de enantema no antro, no corpo e no duodeno além de correlação entre alteração do apetite, a presença de infiltrado inflamatório gástrico e a positividade no teste da urease. Este estudo demonstrou a importância da observação de alguns sinais clínicos como a perda de peso e alterações do apetite no curso da Doença Inflamatória Intestinal. Desta forma, enfatiza-se que cães que apresentem tais sinais clínicos devem ter a Doença Inflamatória Intestinal incluída no grupo de diagnósticos diferenciais evitando, com isso, negligenciar uma enfermidade que, cada vez mais, acomete animais de pequeno porte.(AU)

The aim of this study was to evaluate macro and microscopic gastrointestinal mucosa of domiciled dogs, with chronic gastrointestinal symptoms by endoscopy and histopathological evaluation, correlating clinical signs, macro and microscopy characteristics/aspects/changes of duodenal and gastric mucosa. Twenty dogs of different breeds were evaluated with with chronic characteristic signs of Inflammatory Bowel Disease (IBD), being 7 males and 13 females, with ages ranging from 1.7 to 15.8 years old. The study was prospective and cross-sectional, conducted in dogs treated at the Teaching Veterinary Medicine Hospital of the Universidade Federal Fluminense (HUVET-UFF) and private clinics in the city of Rio de Janeiro. Gastroduodenal mucosal samples were obtained by endoscopic biopsy and were processed by routine histological technique and stained with hematoxylin- eosin and Giemsa. The samples were submitted to histopathological analysis for the detection of spiral bacteria suggestive of Helicobacter spp. The rapid urease test was also performed. The clinical signs, the macro and microscopic findings were compared and correlated. In this study, we established a positive correlation between weight loss and the presence of erythema in the antrum, body and duodenum as well as correlation between change in appetite and the presence of gastric inflammatory infiltrate and positivity in the urease test. This study demonstrated the importance of the observation of some clinical signs such as weight loss and appetite changes in the course of IBD. Thus, it is emphasized that dogs showing these clinical signs should have the IBD included in the differential diagnoses group avoiding thereby neglecting a disease that increasingly affects small animals.(AU)

Colonoscopy in the diagnosis of acute lower gastrointestinal bleeding / A colonoscopia no diagnóstico da hemorragia digestiva baixa aguda

Lower gastrointestinal bleeding is defined as a bleeding originated from a source distal to the Treitz ligament and the colonoscopy is well established as the diagnostic procedure of choice. Objective: To evaluate the results of colonoscopies performed to diagnose the cause of acute lower gastrointestinal bleeding in a general hospital at Mato Grosso do Sul. Material and methods: Colonoscopy procedures performed in the Endoscopy service of the Hospital Regional de Mato Grosso do Sul in those patients admitted due to an acute lower gastrointestinal bleeding from January 2014 to December 2015 were analyzed retrospectively. The studied variables were age, gender, diagnosis and localization of the lesion. Results: The mean age was 66 years, and there was a little predominance of the male gender. Diverticular disease was the main cause of lower gastrointestinal bleeding in this study, followed by cancer, inflammatory gastrointestinal disease, polyps, and angiodysplasia. Conclusion: The colonoscopy showed to be an effective diagnostic method in the case of acute lower gastrointestinal bleeding and a good therapeutic tool in the case of diverticular disease and angiodysplasia.

Hemorragia digestiva baixa é definida como sangramento originado de uma fonte distal ao ligamento de Treitz e a colonoscopia esta bem estabelecida como o seu procedimento diagnóstico de escolha. Objetivo: Avaliar os resultados das colonoscopias realizadas para elucidação diagnóstica dos casos de Hemorragia digestiva baixa aguda em um Hospital Geral de Mato Grosso do Sul. Materiais e métodos: Foram analisadas, de forma retrospectiva, as colonoscopias realizadas nos pacientes internados devido à hemorragia digestiva baixa aguda, no período de janeiro de 2014 a dezembro de 2015, no serviço de endoscopia digestiva do Hospital Regional de Mato Grosso do Sul. As variáveis estudadas foram a idade, sexo, diagnóstico e localização da lesão. Resultados: A média de idade foi de 66 anos, com uma discreta predominância do sexo masculino. A doença diverticular foi a principal causa de hemorragia digestiva baixa nesse estudo, seguido de neoplasias, doença inflamatória intestinal, pólipos e angiodisplasia. Conclusão: A colonoscopia mostrou-se como método efetivo no diagnóstico dos casos de Hemorragia digestiva baixa aguda e como uma boa ferramenta terapêutica também nos casos de angiodisplasia.

Caracterización y hallazgos endoscópicos e histopatológicos de enfermedad inflamatoria intestinal en el Instituto Salvadoreño del Seguro Social / Characterization of endoscopic and histopathological findings of inflammatory bowel disease at the "Instituto Salvadoreño del Seguro Social"

Enfermedad inflamatoria intestinal (EII) comprende 2 entidades a saber: colitis ulcerativa (CU) y la enfermedad de Crohn (EC). La prevalencia e incidencia de estas entidades clínicas varían ampliamente en función de la etnia, localización geográfica y otros factores. En América Latina existen pocos informes sobre la epidemiología de EII, en nuestro país no existen datos reales de la existencia de esta patología, si bien es cierto de acuerdo con los registros del Instituto Salvadoreño del Seguro Social (ISSS) al mes de mayo del 2012, se está cubriendo cerca del 1.6 millones de asegurados en general, con un crecimiento esperado del 2.8% para el último año. Aunque se ha sugerido una menor incidencia y una evolución más benigna de la enfermedad en América Latina. El objetivo principal es "determinar la concordancia de los hallazgos endoscópicos e histopatológicos de la enfermedad inflamatoria intestinal del servicio de Gastroenterología y el departamento de patología del ISSS, en el período del 2008 al 2013." Mejorando en conjunto el trabajo del servicio de gastroenterología y patología para optimizar la concordancia de los resultados endoscópicos e histopatológicos con los cuales se puedan implementar una mejor categorización de los pacientes con EII y de esta manera poder dar un tratamiento oportuno y específico, además de mantener un registro actualizado. Dicha información se obtendrá a través de los estudios colonoscópicos realizados a los pacientes, comparando los resultados histopatológicos y macroscópicos se caracterizará y se establecerá así una base de datos confiable y actualizado de los pacientes con EII

Errores frecuentes en el diagnóstico y tratamiento de los pacientes con enfermedad inflamatoria intestinal / Common errores in the diagnosis and treatment of patients with inflammatory bowel disease

El creciente aumento de pacientes con enfermedad inflamatoria intestinal (EII), sumado a la multiplicidad de alternativas terapéuticas y a la poca experiencia en general de los médicos para tratar estas patologías, ya que son enfermedades emergentes, ha facilitado que se cometan errores tanto en el diagnóstico como en el tratamiento de las EII. En este artículo, se presentarán los más frecuentes e importantes, según la experiencia del autor, con el objeto de corregir estas conductas y alertar a los equipos médicos sobre éstas. El listado incluye errores cometidos en la historia clínica, laboratorio general, endoscopia y tratamiento.

The increasing number of patients with inflammatory bowel disease (IBD), plus the multiplicity of therapeutic alternatives and the low experience of doctors to treat these conditions as they are emerging diseases, have facilitated errors in diagnosis and treatment of IBD. This article will show the most frequent and important ones according to the author's experience, in order to correct these behaviors and alert medical teams about them. The list includes errors in medical history, general laboratory, endoscopy and treatment.

El rol de la endoscopia avanzada en enfermedades inflamatorias intestinales: terapéutica y vigilancia de neoplasias / The role of advanced endoscopy in inflammatory bowel diseases: therapeutic and neoplasms surveillance

Las enfermedades inflamatorias intestinales representan una patología de alta morbilidad. Esto debido a que se asocia a mayor su riesgo de desarrollo de neoplasias tanto colorrectales como colangiocarcinoma, desarrollo de complicaciones como fístulas, abscesos, estenosis intestinales espontáneas o postoperatorias y estenosis biliares en aquellas asociadas a colangitis esclerosante primaria. El rol del endoscopista avanzado en este grupo de pacientes se encuentra en la vigilancia de ambas neoplasias y en el tratamiento endoscópico de las complicaciones ya mencionadas. En relación a la vigilancia de cáncer colorrectal, existen distintas recomendaciones internacionales respecto a los intervalos y las técnicas de vigilancia, situándose la cromoendoscopia como método de elección emergente en los últimos años. Es importante destacar la publicación del uso de nueva nomenclatura para los hallazgos colonoscópicos durante la vigilancia del cáncer colorectal, abandonando los conceptos de DALM o lesiones o masas asociadas a displasia, lesiones tipo adenoma o no adenomatosas.

Inflammatory bowel diseases represent a high morbidity pathology given their high risk of developing both colorectal cancer and cholangiocarcinoma, besides the development of fistulas, abscesses, spontaneous or postoperative intestinal stenosis and biliary strictures in patients diagnosed with primary sclerosant cholangitis. The advanced endoscopist's rol in this group of patients lies within surveillance of both neoplasms and the endoscopic treatment of complications already mentioned. In relation to surveillance of colorectal cancer, there are various international recommendations regarding surveillance intervals and techniques, with chromoendoscopy emerging as a method of choice in recent years. It is important to highlight the use of new nomenclature for colonoscopic findings during surveillance, abandoning concepts as DALM, adenoma-like lesions or non adenoma-like lesions.

Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study / Teste calprotectina fecal semiquantitativa na síndrome do intestino irritável pós-infecciosa e não pós-infecciosa: estudo transversal

CONTEXT AND OBJECTIVE:The presence of a certain degree of inflammation in the gut wall is now accepted in irritable bowel syndrome (IBS). Fecal calprotectin is considered to be a reliable test for detecting intestinal inflammation. Our aim was to assess the presence of inflammation in postinfectious IBS (PI-IBS), compared with non-postinfectious IBS (NPI-IBS). A secondary objective was to determine the usefulness of a rapid fecal calprotectin test in inflammatory bowel diseases (IBD).DESIGN AND SETTING:This was a cross-sectional study. Patients with IBS and IBD at a single tertiary gastroenterology center were prospectively included in this study.METHODS:116 patients with Rome III IBS score (76 females; 48 ± 12 years) were investigated; 24 patients (15 females) had PI-IBS. Intestinal inflammation was assessed using the semiquantitative fecal calprotectin test. The results were expressed as T1, T2 or T3 according to the severity of inflammation (< 15 μg/g; 15-60 μg/g; > 60 μg/g). Using the same test, we evaluated 20 patients with IBD (12 males; 47 ± 13 years).RESULTS:None of the patients with IBS had a T2 or T3 positive test. Among PI-IBS patients, 33% had a T1 positive test. Among NPI-IBS patients, 9.8% had a T1 positive test, which was significantly different to PI-IBS. The calprotectin test was positive in all IBD patients: 80% with T3, 10% with T2 and 10% with T1.CONCLUSIONS:Using a semiquantitative test for fecal calprotectin, positive tests were more frequent in PI-IBS patients than in NPI-IBS patients.

CONTEXTO E OBJETIVO:A presença de certo grau de inflamação na parede do intestino é agora aceita na síndrome do intestino irritável (SII). A calprotectina fecal é considerada teste confiável para detectar inflamação intestinal. Nosso objetivo foi avaliar a presença de inflamação na SII pós-infecciosa (SII-PI), em comparação com a SII não pós-infecciosa (SII-NPI). Um objetivo secundário foi determinar a utilidade de um teste rápido fecal da calprotectina em doenças inflamatórias intestinais (DII).TIPO DE ESTUDO E LOCAL:Este foi um estudo transversal. Pacientes com SII e DII em um único centro terciário de gastroenterologia foram prospectivamente incluídos neste estudo.MÉTODOS:116 pacientes com escore Roma III de SII (76 mulheres, 48 ± 12 anos) foram investigados; 24 pacientes (15 mulheres) tinham SII-PI. Inflamação intestinal foi avaliada pelo teste semi-quantitativo de calprotectina fecal. Os resultados foram expressos como T1, T2 ou T3 de acordo com a gravidade da inflamação (< 15 μg/g; 15-60 mg/g; > 60 mg/g). Usando o mesmo teste, foram avaliados 20 pacientes com DII (12 homens, 47 ± 13 anos).RESULTADOS:Nenhum dos pacientes com SII teve um teste positivo T2 ou T3. Na PI-IBS, 33% tiveram um teste positivo T1. Entre os pacientes SII-NPI, teste T1 positivo estava presente em 9,8%, taxa significativamente diferente quando comparada com SII-PI. O teste de calprotectina foi positivo em todos os pacientes com DII: 80% com T3, 10% com T2 e 10% com T1.CONCLUSÕES:Usando teste semi-quantitativo para calprotectina fecal, relatamos positividade em pacientes SII-PI com mais frequência que em pacientes SII-NPI.

Enfermedad inflamatoria intestinal en pacientes mayores de 60 años: ¿es una enfermedad diferente? / Differences by age in clinical features of inflammatory bowel disease

Background: Approximately, 15% of patients with Inflammatory Bowel Disease (IBD) are diagnosed at 60 years of age or more. Aim: To characterize and compare clinical variables between patients with IBD aged 60 years or more and their younger counterparts. Material and Methods: Retrospective study based on a registry of IBD patients diagnosed between the years 1976 and 2014. Results: Four hundred and nine IBD patients were included. Among them, 294 had Ulcerative Colitis (UC), 104 had Crohn s Disease (CD) and eleven had an indeterminate IBD. Forty-six patients (11.2%) were older than 60 years and 16 (3.9%) had been diagnosed after this age. When comparing patients by age, those aged 60 years or more had a higher frequency of CD and indeterminate IBD (p < 0.01) and a lower ileocolic location in CD (p = 0.02). Both groups were similar in terms of hospitalization due to IBD flare, surgery, use of steroids, immunosuppressive or biological therapies and drug-related adverse events. When analyzing age at diagnosis of IBD, patients diagnosed at ages of 60 years or more had a lower frequency of UC (p < 0.01), a higher frequency of exclusive colonic involvement (p = 0.01), and lower use of mesalamine (p < 0.01). There were no differences in drug-related adverse events, hospitalizations due to IBD flares and surgery according to age at diagnosis. Conclusions: In this population, clinical features of IBD in older patients were similar to those in younger patients.

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms / Calprotectina fecal: níveis para o diagnóstico etiológico em pacientes brasileiros com sintomas gastrointestinais

Background Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit Results A total of 279 patients were included in the study, with median age of 39 years (range, 18 to 78 years). After clinical and laboratorial evaluation and considering the final diagnosis, patients were allocated into the following groups: a) Irritable Bowel Syndrome: 154 patients (102 female and 52 male subjects). b) Inflammatory Bowel Diseases group: 112 patients; 73 with Crohn’s disease; 38 female and 35 male patients; 52.1% (38/73) presented active disease, and 47.9% (35/73) had disease in remission and 39 patients with ulcerative colitis;19 female and 20 male patients; 48.7% (19/39) classified with active disease and 49.3% (20/39) with disease in remission. A significant difference (P<0.001) was observed between the median value of fecal calprotectin in Irritable Bowel Syndrome group that was 50.5 µg/g (IQR=16 - 294 µg/g); 405 µg/g (IQR=29 - 1980 µg/g) in Crohn’s disease patients and 457 µg/g (IQR=25 - 1430 µg/g) in ulcerative colitis patients. No difference was observed between the values found in the patients with Crohn’s disease and ulcerative colitis. Levels of fecal calprotectin were significantly ...

Contexto A calprotectina fecal é um biomarcador que pode fornecer informações importantes para o médico, inclusive no atendimento primário, no diagnóstico diferencial de distúrbios gastrointestinais, principalmente as doenças inflamatórias intestinais e a síndrome do intestino irritável. Objetivos Investigar prospectivamente, em adultos brasileiros com queixas gastrointestinais, o valor da calprotectina fecal como biomarcador para o diagnóstico diferencial de distúrbios funcionais e orgânicos e correlacionar as concentrações com a atividade de doenças inflamatórias intestinais. Método O estudo incluiu pacientes consecutivos que apresentavam queixas gastrointestinais e que a dosagem da calprotectina fecal foi recomendada. A dosagem da calprotectina fecal foi obtida utilizando-se o kit ELISA Buhlmann, (Basel, Suiça). Resultados Um total de 279 foram incluídos no estudo, com idade média de 39 anos (variando entre 18 a 78 anos). Após avaliação clínica e laboratorial, e considerando o diagnóstico final, os pacientes foram alocados nos seguintes grupos: a) Grupo Síndrome do Intestino Irritável: 154 pacientes (102 do sexo feminino e 52 indivíduos do sexo masculino). b) grupo Doenças Inflamatórias Intestinais: 112 pacientes; 73 com doença de Crohn; 38 do sexo feminino e 35 pacientes do sexo masculino; 52,1% (38/73) apresentavam doença ativa, e 47,9% (35/73) tiveram a doença em remissão e 39 pacientes com retocolite ulcerativa; 19 do sexo feminino e 20 pacientes do sexo masculino; 48,7% (19/39) classificadas com a doença ativa e 49,3% (20/39) com a doença em remissão. Foi observada uma diferença significativa (P<0,001) entre o valor médio de calprotectina fecal no grupo Síndrome do Intestino Irritável que foi de 50,5 µg/g (16 a 294 µg/g); 405 µg/g (29 a 1980 µg/g), em pacientes com doença de Crohn e 457 µg/g (25 a1430 µg/g), em pacientes com retocolite ulcerativa. Não foram observadas diferenças entre os valores encontrados nos pacientes com ...

Prevalência de alterações bucais nas doenças gastrointestinais inflamatórias crônicas: análise de 10 casos / Prevalence of oral abnormalities in chronic inflammatory gastrointestinal diseases: analysis of 10 cases

Introdução: Doenças gastrointestinais inflamatórias crônicas (DGIC) é um grupo de doenças em que se enquadram a doença de Crohn (DCr), a colite ulcerativa e a doença celíaca (DC) cuja origem ainda é incerta e são caracterizadas por terem um curso clínico crônico e intercalarem períodos de remissão com episódios agudos. Por sua vez, as manifestações bucais nas DGIC são achados clínicos comuns, podendo apresentar ulcerações e defeitos de desenvolvimento em esmalte, sendo aquelas, as lesões mais frequentes. Objetivo: Verificar a presença de alterações bucais em pacientes com DGIC. Métodos: A coleta de informações foi obtida através da aplicação de um questionário e de exame clínico em 10 pacientes diagnosticados com DGIC. Resultados: Os pacientes com DGIC apresentaram líquen plano oral, língua fissurada, dente supranumerário, torus palatino, microdentes, agenesia dentária, disfunção da ATM, granuloma piogênico, linha Alba e dente rosa de Mummery. O defeito de desenvolvimento de esmalte mais frequente nos pacientes com DC foi a opacidade difusa, na DCr foi a opacidade demarcada e na colite ulcerativa foram a hipoplasia e outros defeitos. Conclusão: De fato, as manifestações bucais e dentárias podem fazer parte do quadro das DGIC sendo importante a integração multidisciplinar no tratamento e acompanhamento desses pacientes. Além disso, foi evidente a relação entre alterações de desenvolvimento de esmalte e as DGIC (AU).

Introduction: Chronic gastrointestinal inflammatory diseases (CGID) is a group of diseases that are Crohn's disease (CrD), ulcerative colitis and celiac disease (CD) whose origin is still uncertain and are characterized by having a chronic clinical course and interleave periods of remission with acute episodes. Oral manifestations in CGID are common clinical findings and may have ulcerations, enamel developmental defects, ulcers are the most frequent injuries. Objective: Verify the presence of oral abnormalities in patients with CGID and oral manifestations. Methods: Data collection was obtained through a questionnaire and clinical examination in 10 patients diagnosed with CGID. Results: Patients with CGID presented oral lichen planus, fissured tongue, supernumerary tooth, palatal torus, micro tooth, tooth agenesis, TMJ disorder, pyogenic granuloma, Alba line and rose Mummery tooth. The most frequent defect enamel development in patients with CD was diffuse opacity for CrD was demarcated opacity were ulcerative colitis and hypoplasia and other defects. Conclusion: In fact, the oral and dental manifestations may be part of CGID framework is important multidisciplinary integration in the treatment and monitoring of these patients. Furthermore, it was evident relationship between enamel development and changes CGID (AU).

Quality of Care in Inflammatory Bowel Disease / 대한소화기학회지

Since inflammatory bowel disease (IBD) is a chronic and relapsing disorder, maintaining high quality of care plays an important role in the management of patients with IBD. To develop process-based quality indicator set to improve quality of care, the indicator should be based directly on evidence and consensus. Initially, ImproveCareNow group demonstrated quality improvement by learning how to apply quality improvement methods to improve the care of pediatric patients with IBD. The American Gastroenterological Association has developed adult IBD physician performance measures set and Crohn's and Colitis Foundation of America (CCFA) has developed a set of ten most highly rated process and outcome measures. Recently, The Emerging Practice in IBD Collaborative (EPIC) group generated defining quality indicators for best-practice management of IBD in Canada. Quality of Care through the Patient's Eyes (QUOTE-IBD) was developed as a questionnaire to measure quality of care through the eyes of patients with IBD, and it is widely used in European countries. The current concept of quality of care as well as quality indicator will be discussed in this article.

Ideal Vaccination Strategy in Inflammatory Bowel Disease / 대한소화기학회지

Inflammatory bowel disease (IBD) is a long-standing disease that often requires long-term use of immunosuppressive agents including immunomodulators (such as azathioprine, 6-mercaptopurine and methotrexate) and tumor necrosis factor-alpha inhibitors (such as infliximab and adalimumab). Introduction of immunosuppressive therapies, however, involves the risk of host susceptibility to opportunistic infections in this patient population. Therefore, adequate immunization for vaccine-preventable infectious diseases is currently recommended for all patients with IBD and is emerging as an important target for quality improvements in IBD care. However, ongoing issues regarding underuse of immunization, safety and efficacy of vaccines in patients with IBD remain. For quality improvements in IBD care, all physicians should follow the recent immunization guidelines proposed by professional IBD societies. Additionally, there are ongoing needs for intensive educational programs regarding a role of immunization in long-term care of IBD and up-to-date immunization guidelines. Immunization status should be checked at the time of diagnosis of IBD and timely vaccination before initiation of immunosuppressive therapies can be a practical solution for maximizing the efficacy of vaccination at this point. Inactivated vaccines can be used safely irrespective of immunization status of patients, while attenuated vaccines are contraindicated in patients on immunosuppressive therapies. This article reviews an ideal strategy for vaccinating patients with IBD based on the currently recommended immunization guidelines.

Discordance between Patients and Parents Regarding the Perceived Causes of Clinical Relapse in Young Inflammatory Bowel Disease Patients / 대한소화기학회지

BACKGROUND/AIMS: Relapse in inflammatory bowel disease (IBD) is not predictable, although several factors have been suggested. The aims of the current study were to assess and compare the possible causes of clinical relapse as perceived by patients and parents. METHODS: Of 107 young (<35 years old) IBD patients, 26 patients who experienced recent (<3 month) relapse and their parents completed a questionnaire at the same time. Baseline characteristics and clinical manifestations were reviewed and the most common causes of relapse as perceived by patients and parents were compared. RESULTS: Median patient age was 22.5 years and the male to female ratio was 17:9. Crohn's disease was diagnosed in 23 patients and ulcerative colitis in the other three patients. Mean disease duration was 39.8+/-30.3 months. Eighteen (69.2%) patients experienced stress before relapse. Fifteen (57.7%) parents thought that their children experienced stress before relapse. Agreement between patients and parents for non-adherence to medication and stress was 100% and 73.1%, respectively. Stress was considered the most likely cause of relapse in both groups. Discordance rate between parents and patients with respect to main causes of relapse was 40.4%. CONCLUSIONS: Stress was perceived to be the most common condition noted before clinical relapse in young IBD patients and their parents. However, the discordance rate between patients and parents with respect to the main causes of relapse was 40.4%. This result suggests a considerable difference in terms of disease understanding between young IBD patients and parents.